Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan 15;5(1):27-47.
doi: 10.3390/cancers5010027.

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors

Florence Schaffner  1 , Anne Marie Ray, Monique Dontenwill
Affiliations

Integrin α5β1, the Fibronectin Receptor, as a Pertinent Therapeutic Target in Solid Tumors

Florence Schaffner et al. Cancers (Basel). .

Abstract

Integrins are transmembrane heterodimeric proteins sensing the cell microenvironment and modulating numerous signalling pathways. Changes in integrin expression between normal and tumoral cells support involvement of specific integrins in tumor progression and aggressiveness. This review highlights the current knowledge about α5β1 integrin, also called the fibronectin receptor, in solid tumors. We summarize data showing that α5β1 integrin is a pertinent therapeutic target expressed by tumoral neovessels and tumoral cells. Although mainly evaluated in preclinical models, α5β1 integrin merits interest in particular in colon, breast, ovarian, lung and brain tumors where its overexpression is associated with a poor prognosis for patients. Specific α5β1 integrin antagonists will be listed that may represent new potential therapeutic agents to fight defined subpopulations of particularly aggressive tumors.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer. 2010;10:9–22. doi: 10.1038/nrc2748. - DOI - PMC - PubMed
    1. Goodman S.L., Picard M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 2012;33:405–412. doi: 10.1016/j.tips.2012.04.002. - DOI - PubMed
    1. Aoudjit F., Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012;2012:283181. - PMC - PubMed
    1. Avraamides C.J., Garmy-Susini B., Varner J.A. Integrins in angiogenesis and lymphangiogenesis. Nat. Rev. Cancer. 2008;8:604–617. doi: 10.1038/nrc2353. - DOI - PMC - PubMed
    1. Chamberlain M.C., Cloughsey T., Reardon D.A., Wen P.Y. A novel treatment for glioblastoma: Integrin inhibition. Expert Rev. Neurother. 2012;12:421–435. doi: 10.1586/ern.11.188. - DOI - PubMed